Pain is a debilitating condition that affects the life of one in five Australians and has significant socioeconomic impact. Currently available pain killers often do not work, or have intolerable side effects including sedation and addiction. We have discovered a novel compound that avoids these side effects and provides effective analgesia as well as opioid-sparing effects in a number of relevant animal models. The aim of this project is to progress the compound towards clinical development.
Enamel Remineralisation And Prebiosis By A Novel Biomimetic System
Funder
National Health and Medical Research Council
Funding Amount
$800,585.00
Summary
Tooth decay and erosion involve loss of tooth mineral and are major public health problems.The project will involve the testing of a prototype professional product “Tooth Mousse Professional” to repair early stages of mineral loss. It is anticipated that this project will result in the development of a system with substantially superior properties for the non-invasive treatment of early tooth decay and erosion. The system will also encourage the growth of beneficial bacteria in the mouth.
Pancreatic Targeting Of IL-22 Therapy For Diabetes
Funder
National Health and Medical Research Council
Funding Amount
$484,644.00
Summary
Type 2 diabetes is one of the largest problems facing health care and presents an enormous therapeutic market. Our approach with IL-22 fights the disease at the core of the problem in the pancreatic ?-cells that make insulin. Our patent focuses on targeting IL-22 to the ?-cells which promises to maximise therapeutic benefits while minimising potential adverse effects in other tissues. Independently, and in collaboration with Novo Nordisk, we are making prototype drugs to achieve this.